Triple-Hormone-Receptor Agonist Retatrutide for Obesity

  • Bisson, Arnaud M.D.
  • Fauchier, Grégoire M.D.
  • Fauchier, Laurent M.D.

  • Centre Hospitalier Régional Universitaire de Tours, Tours, France

Dr. Bisson reports having received lecture fees from Alnylam, AstraZeneca, Bayer, BMS/Pfizer, Medtronic, and Vifor Pharma. Dr. L. Fauchier reports having received consulting fees from Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis, Novo, and Laboratoire X.O and lecture fees from AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis, and Zoll. No other potential conflict of interest relevant to this letter was reported.

New England Journal of Medicine 389(17):p 1628, October 26, 2023. | DOI: 10.1056/NEJMc2310645

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

  • Jastreboff, Ania M. M.D., Ph.D.
  • Kaplan, Lee M. M.D., Ph.D.
  • Frías, Juan P. M.D.
  • Wu, Qiwei Ph.D.
  • Du, Yu Ph.D.
  • Gurbuz, Sirel M.D.
  • Coskun, Tamer M.D., Ph.D.
  • Haupt, Axel M.D., Ph.D.
  • Milicevic, Zvonko M.D.
  • Hartman, Mark L. M.D.
New England Journal of Medicine 389(6):p 514-526, August 10, 2023. | DOI: 10.1056/NEJMoa2301972
Copyright © 2023 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF